{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:08:03Z","timestamp":1772150883317,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,23]],"date-time":"2020-12-23T00:00:00Z","timestamp":1608681600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,12,23]],"date-time":"2020-12-23T00:00:00Z","timestamp":1608681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Deutsches Herzzentrum M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Aims<\/jats:title>\n                <jats:p>To investigate the clinical outcomes associated with an antithrombotic therapy with or without clopidogrel after transcatheter aortic valve replacement (TAVR).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods and results<\/jats:title>\n                <jats:p>This is a study-level meta-analysis including all randomized trials investigating antithrombotic regimens after TAVR. The protocol was registered with PROSPERO (CRD42020191036). We searched electronic scientific databases for eligible studies. The primary outcome was all-cause death. Main secondary outcome was major bleeding. Other outcomes were life-threatening (or disabling) bleeding, myocardial infarction (MI) and stroke. Six eligible trials randomly allocated 3056 TAVR patients to aspirin or oral anticoagulation (OAC) with clopidogrel (<jats:italic>n<\/jats:italic>\u2009=\u20091525) versus aspirin and\/or OAC without clopidogrel (<jats:italic>n<\/jats:italic>\u2009=\u20091531). In the overall estimates, an antithrombotic therapy with clopidogrel versus without displayed a comparable risk of all-cause death [Risk Ratio\u2014RR\u2009=\u20090.83, 95% Confidence intervals\u2014CI (0.57\u20131.20); <jats:italic>P<\/jats:italic>\u2009=\u20090.25] and major bleeding [RR\u2009=\u20091.33, 95% CI (0.61\u20132.92); <jats:italic>P<\/jats:italic>\u2009=\u20090.39]. However, the combination of aspirin or OAC with clopidogrel doubled the risk of major bleeding as compared to aspirin or OAC without clopidogrel [RR\u2009=\u20092.08, 95% CI (1.27\u20133.42); <jats:italic>P<\/jats:italic>\u2009=\u20090.015, <jats:italic>P<\/jats:italic> for interaction\u2009=\u20090.021]. Treatment strategies did not differ with respect to the risk of life-threatening bleeding, MI and stroke.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In patients receiving TAVR, a therapeutic strategy of aspirin or OAC with clopidogrel significantly increases the risk of major bleeding without impact on mortality and ischemic outcomes compared to aspirin or OAC without clopidogrel. The performance of different antithrombotic regimens in terms of long-term clinical outcomes and bioprosthesis valve function requires further investigation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphic abstract<\/jats:title>\n                <jats:p>Forest plots from pairwise and network meta-analyses associated with an antithrombotic therapy with or without clopidogrel Risk ratio for all outcomes of interest calculated with the pairwise meta-analysis (left side) and for main outcomes calculated with the network meta-analysis (right side) in patients allocated to an antithrombotic therapy with clopidogrel or without. The diamonds indicate the point estimate and the left and the right ends of the lines the [95% CI]. CI: Confidence intervals; OAC; oral anticoagulation.<\/jats:p>\n                \n              <\/jats:sec>","DOI":"10.1007\/s00392-020-01791-x","type":"journal-article","created":{"date-parts":[[2020,12,23]],"date-time":"2020-12-23T19:02:55Z","timestamp":1608750175000},"page":"14-22","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Antithrombotic therapy with or without clopidogrel after transcatheter aortic valve replacement. A meta-analysis of randomized controlled trials"],"prefix":"10.1007","volume":"111","author":[{"given":"Costanza","family":"Pellegrini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erion","family":"Xhepa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gjin","family":"Ndrepepa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hector","family":"Alvarez-Covarrubias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Kufner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Lena","family":"Lahmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Rheude","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Himanshu","family":"Rai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N. Patrick","family":"Mayr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heribert","family":"Schunkert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adnan","family":"Kastrati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Joner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Cassese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,12,23]]},"reference":[{"issue":"23","key":"1791_CR1","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1056\/NEJMoa1103510","volume":"364","author":"CR Smith","year":"2011","unstructured":"Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, Williams M, Dewey T, Kapadia S, Babaliaros V, Thourani VH, Corso P, Pichard AD, Bavaria JE, Herrmann HC, Akin JJ, Anderson WN, Wang D, Pocock SJ (2011) Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 364(23):2187\u20132198","journal-title":"N Engl J Med"},{"issue":"14","key":"1791_CR2","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1056\/NEJMoa1700456","volume":"376","author":"MJ Reardon","year":"2017","unstructured":"Reardon MJ, Van Mieghem NM, Popma JJ, Kleiman NS, Sondergaard L, Mumtaz M, Adams DH, Deeb GM, Maini B, Gada H, Chetcuti S, Gleason T, Heiser J, Lange R, Merhi W, Oh JK, Olsen PS, Piazza N, Williams M, Windecker S, Yakubov SJ, Grube E, Makkar R, Lee JS, Conte J, Vang E, Nguyen H, Chang Y, Mugglin AS, Serruys PW, Kappetein AP (2017) Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. N Engl J Med 376(14):1321\u20131331","journal-title":"N Engl J Med"},{"issue":"18","key":"1791_CR3","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1056\/NEJMoa1814052","volume":"380","author":"MJ Mack","year":"2019","unstructured":"Mack MJ, Leon MB, Thourani VH, Makkar R, Kodali SK, Russo M, Kapadia SR, Malaisrie SC, Cohen DJ, Pibarot P, Leipsic J, Hahn RT, Blanke P, Williams MR, McCabe JM, Brown DL, Babaliaros V, Goldman S, Szeto WY, Genereux P, Pershad A, Pocock SJ, Alu MC, Webb JG, Smith CR, Investigators P (2019) Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med 380(18):1695\u20131705","journal-title":"N Engl J Med"},{"issue":"45","key":"1791_CR4","doi-asserted-by":"publisher","first-page":"3341","DOI":"10.1093\/eurheartj\/ehx390","volume":"38","author":"P Vranckx","year":"2017","unstructured":"Vranckx P, Windecker S, Welsh RC, Valgimigli M, Mehran R, Dangas G (2017) Thrombo-embolic prevention after transcatheter aortic valve implantation. Eur Heart J 38(45):3341\u20133350","journal-title":"Eur Heart J"},{"issue":"36","key":"1791_CR5","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1093\/eurheartj\/ehx391","volume":"38","author":"H Baumgartner","year":"2017","unstructured":"Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, Iung B, Lancellotti P, Lansac E, Rodriguez Munoz D, Rosenhek R, Sjogren J, Tornos Mas P, Vahanian A, Walther T, Wendler O, Windecker S, Zamorano JL (2017) 2017 ESC\/EACTS guidelines for the management of valvular heart disease. Eur Heart J 38(36):2739\u20132791","journal-title":"Eur Heart J"},{"issue":"2","key":"1791_CR6","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.jacc.2017.03.011","volume":"70","author":"RA Nishimura","year":"2017","unstructured":"Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Fleisher LA, Jneid H, Mack MJ, McLeod CJ, O\u2019Gara PT, Rigolin VH, Sundt TM 3rd, Thompson A (2017) 2017 AHA\/ACC focused update of the 2014 aha\/acc guideline for the management of patients with valvular heart disease: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines. J Am Coll Cardiol 70(2):252\u2013289","journal-title":"J Am Coll Cardiol"},{"key":"1791_CR7","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.ijcard.2016.11.104","volume":"228","author":"E Cerrato","year":"2017","unstructured":"Cerrato E, Nombela-Franco L, Nazif TM, Eltchaninoff H, Sondergaard L, Ribeiro HB, Barbanti M, Nietlispach F, De Jaegere P, Agostoni P, Trillo R, Jimenez-Quevedo P, D\u2019Ascenzo F, Wendler O, Maluenda G, Chen M, Tamburino C, Macaya C, Leon MB, Rodes-Cabau J (2017) Evaluation of current practices in transcatheter aortic valve implantation: the WRITTEN (WoRldwIde TAVI ExperieNce) survey. Int J Cardiol 228:640\u2013647","journal-title":"Int J Cardiol"},{"issue":"12","key":"1791_CR8","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1016\/j.amjcard.2011.07.049","volume":"108","author":"GP Ussia","year":"2011","unstructured":"Ussia GP, Scarabelli M, Mule M, Barbanti M, Sarkar K, Cammalleri V, Imme S, Aruta P, Pistritto AM, Gulino S, Deste W, Capodanno D, Tamburino C (2011) Dual antiplatelet therapy versus aspirin alone in patients undergoing transcatheter aortic valve implantation. Am J Cardiol 108(12):1772\u20131776","journal-title":"Am J Cardiol"},{"issue":"3","key":"1791_CR9","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.ijcard.2014.04.170","volume":"174","author":"E Stabile","year":"2014","unstructured":"Stabile E, Pucciarelli A, Cota L, Sorropago G, Tesorio T, Salemme L, Popusoi G, Ambrosini V, Cioppa A, Agrusta M, Catapano D, Moscariello C, Trimarco B, Esposito G, Rubino P (2014) SAT-TAVI (single antiplatelet therapy for TAVI) study: a pilot randomized study comparing double to single antiplatelet therapy for transcatheter aortic valve implantation. Int J Cardiol 174(3):624\u2013627","journal-title":"Int J Cardiol"},{"issue":"13","key":"1791_CR10","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/j.jcin.2017.04.014","volume":"10","author":"J Rodes-Cabau","year":"2017","unstructured":"Rodes-Cabau J, Masson JB, Welsh RC, Garcia Del Blanco B, Pelletier M, Webb JG, Al-Qoofi F, Genereux P, Maluenda G, Thoenes M, Paradis JM, Chamandi C, Serra V, Dumont E, Cote M (2017) aspirin versus aspirin plus clopidogrel as antithrombotic treatment following transcatheter aortic valve replacement with a balloon-expandable valve: the arte (aspirin versus aspirin + clopidogrel following transcatheter aortic valve implantation) randomized clinical trial. JACC Cardiovasc Interv 10(13):1357\u20131365","journal-title":"JACC Cardiovasc Interv"},{"issue":"2","key":"1791_CR11","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa1911425","volume":"382","author":"GD Dangas","year":"2020","unstructured":"Dangas GD, Tijssen JGP, Wohrle J, Sondergaard L, Gilard M, Mollmann H, Makkar RR, Herrmann HC, Giustino G, Baldus S, De Backer O, Guimaraes AHC, Gullestad L, Kini A, von Lewinski D, Mack M, Moreno R, Schafer U, Seeger J, Tchetche D, Thomitzek K, Valgimigli M, Vranckx P, Welsh RC, Wildgoose P, Volkl AA, Zazula A, van Amsterdam RGM, Mehran R, Windecker S (2020) A controlled trial of rivaroxaban after transcatheter aortic-valve replacement. N Engl J Med 382(2):120\u2013129","journal-title":"N Engl J Med"},{"issue":"18","key":"1791_CR12","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1056\/NEJMoa1915152","volume":"382","author":"VJ Nijenhuis","year":"2020","unstructured":"Nijenhuis VJ, Brouwer J, Delewi R, Hermanides RS, Holvoet W, Dubois CLF, Frambach P, De Bruyne B, van Houwelingen GK, Van Der Heyden JAS, Tousek P, van der Kley F, Buysschaert I, Schotborgh CE, Ferdinande B, van der Harst P, Roosen J, Peper J, Thielen FWF, Veenstra L, Chan Pin Yin D, Swaans MJ, Rensing B, van \u2019t Hof AWJ, Timmers L, Kelder JC, Stella PR, Baan J, Ten Berg JM (2020) Anticoagulation with or without clopidogrel after transcatheter aortic-valve implantation. N Engl J Med 382(18):1696\u20131707","journal-title":"N Engl J Med"},{"key":"1791_CR13","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA (2011) The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 343:d5928","journal-title":"BMJ"},{"issue":"11","key":"1791_CR14","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1001\/jama.282.11.1054","volume":"282","author":"P Juni","year":"1999","unstructured":"Juni P, Witschi A, Bloch R, Egger M (1999) The hazards of scoring the quality of clinical trials for meta-analysis. JAMA 282(11):1054\u20131060","journal-title":"JAMA"},{"issue":"7","key":"1791_CR15","doi-asserted-by":"publisher","first-page":"e010247","DOI":"10.1136\/bmjopen-2015-010247","volume":"6","author":"J IntHout","year":"2016","unstructured":"IntHout J, Ioannidis JP, Rovers MM, Goeman JJ (2016) Plea for routinely presenting prediction intervals in meta-analysis. BMJ Open 6(7):e010247","journal-title":"BMJ Open"},{"key":"1791_CR16","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","volume":"15","author":"G Rucker","year":"2015","unstructured":"Rucker G, Schwarzer G (2015) Ranking treatments in frequentist network meta-analysis works without resampling methods. BMC Med Res Methodol 15:58","journal-title":"BMC Med Res Methodol"},{"issue":"4","key":"1791_CR17","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","volume":"151","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151(4):264\u2013269","journal-title":"Ann Intern Med"},{"key":"1791_CR18","doi-asserted-by":"crossref","unstructured":"Brouwer J, Nijenhuis VJ, Delewi R, Hermanides RS, Holvoet W, Dubois CLF, Frambach P, De Bruyne B, van Houwelingen GK, Van Der Heyden JAS, Tousek P, van der Kley F, Buysschaert I, Schotborgh CE, Ferdinande B, van der Harst P, Roosen J, Peper J, Thielen FWF, Veenstra L, Chan Pin Yin D, Swaans MJ, Rensing B, van 't Hof AWJ, Timmers L, Kelder JC, Stella PR, Baan J, Ten Berg JM (2020) Aspirin with or without Clopidogrel after Transcatheter Aortic Valve Implantation. N Engl J Med 383(15):1447\u20131457","DOI":"10.1056\/NEJMoa2017815"},{"issue":"10087","key":"1791_CR19","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1016\/S0140-6736(17)30757-2","volume":"389","author":"T Chakravarty","year":"2017","unstructured":"Chakravarty T, Sondergaard L, Friedman J, De Backer O, Berman D, Kofoed KF, Jilaihawi H, Shiota T, Abramowitz Y, Jorgensen TH, Rami T, Israr S, Fontana G, de Knegt M, Fuchs A, Lyden P, Trento A, Bhatt DL, Leon MB, Makkar RR (2017) Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study. Lancet 389(10087):2383\u20132392","journal-title":"Lancet"},{"key":"1791_CR20","doi-asserted-by":"crossref","unstructured":"Saito Y, Nazif T, Baumbach A, Tchetche D, Latib A, Kaple R, Forrest J, Prendergast B, Lansky A (2019) Adjunctive antithrombotic therapy for patients with aortic stenosis undergoing transcatheter aortic valve replacement. JAMA Cardiol 5(1):92\u2013101","DOI":"10.1001\/jamacardio.2019.4367"},{"issue":"2","key":"1791_CR21","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/eurheartj\/ehq406","volume":"32","author":"MB Leon","year":"2011","unstructured":"Leon MB, Piazza N, Nikolsky E, Blackstone EH, Cutlip DE, Kappetein AP, Krucoff MW, Mack M, Mehran R, Miller C, Morel MA, Petersen J, Popma JJ, Takkenberg JJ, Vahanian A, van Es GA, Vranckx P, Webb JG, Windecker S, Serruys PW (2011) Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium. Eur Heart J 32(2):205\u2013217","journal-title":"Eur Heart J"},{"issue":"19","key":"1791_CR22","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1093\/eurheartj\/ehs255","volume":"33","author":"AP Kappetein","year":"2012","unstructured":"Kappetein AP, Head SJ, Genereux P, Piazza N, van Mieghem NM, Blackstone EH, Brott TG, Cohen DJ, Cutlip DE, van Es GA, Hahn RT, Kirtane AJ, Krucoff MW, Kodali S, Mack MJ, Mehran R, Rodes-Cabau J, Vranckx P, Webb JG, Windecker S, Serruys PW, Leon MB (2012) Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. Eur Heart J 33(19):2403\u20132418","journal-title":"Eur Heart J"},{"issue":"2","key":"1791_CR23","doi-asserted-by":"publisher","first-page":"E177","DOI":"10.1002\/ccd.28498","volume":"96","author":"T Kuno","year":"2020","unstructured":"Kuno T, Takagi H, Sugiyama T, Ando T, Miyashita S, Valentin N, Shimada YJ, Kodaira M, Numasawa Y, Kanei Y, Hayashida K, Bangalore S (2020) Antithrombotic strategies after transcatheter aortic valve implantation: Insights from a network meta-analysis. Catheter Cardiovasc Interv 96(2):E177\u2013E186","journal-title":"Catheter Cardiovasc Interv"},{"issue":"5","key":"1791_CR24","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1093\/ejcts\/ezz335","volume":"57","author":"Y Zhu","year":"2020","unstructured":"Zhu Y, Zou Z, Huang Y, Zhang L, Chen H, Li Y, Liu C, Li X, Xu D, Zeng Q (2020) Comparative efficacy and safety of antithrombotic therapy for transcatheter aortic valve replacement: a systematic review and network meta-analysis. Eur J Cardiothorac Surg 57(5):965\u2013976","journal-title":"Eur J Cardiothorac Surg"},{"issue":"1","key":"1791_CR25","doi-asserted-by":"publisher","first-page":"e007411","DOI":"10.1161\/CIRCINTERVENTIONS.118.007411","volume":"12","author":"P Guedeney","year":"2019","unstructured":"Guedeney P, Mehran R, Collet JP, Claessen BE, Ten Berg J, Dangas GD (2019) Antithrombotic therapy after transcatheter aortic valve replacement. Circ Cardiovasc Interv 12(1):e007411","journal-title":"Circ Cardiovasc Interv"},{"issue":"2","key":"1791_CR26","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1056\/NEJMoa1911426","volume":"382","author":"O De Backer","year":"2020","unstructured":"De Backer O, Dangas GD, Jilaihawi H, Leipsic JA, Terkelsen CJ, Makkar R, Kini AS, Veien KT, Abdel-Wahab M, Kim WK, Balan P, Van Mieghem N, Mathiassen ON, Jeger RV, Arnold M, Mehran R, Guimaraes AHC, Norgaard BL, Kofoed KF, Blanke P, Windecker S, Sondergaard L (2020) Reduced Leaflet Motion after Transcatheter Aortic-Valve Replacement. N Engl J Med 382(2):130\u2013139","journal-title":"N Engl J Med"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-020-01791-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-020-01791-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-020-01791-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T16:07:38Z","timestamp":1642522058000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-020-01791-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,23]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["1791"],"URL":"https:\/\/doi.org\/10.1007\/s00392-020-01791-x","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,23]]},"assertion":[{"value":"9 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"HS reports honoraria from MSD SHARP and DOHME, AMGEN, Bayer Vital GmbH, Boehringer Ingelheim, Daiichi Sankyo, Novartis, Servier, Brahms, Bristol-Myers Squibb, Medtronic, Sanofi Aventis, Synlab, Pfizer, institutional grant and honoraria from Astra-Zeneca, and travel grants from Vifor outside the submitted work; MJ reports honoraria from Biotronik, Orbus Neich, Boston Scientific, Medtronic, Astra Zeneca, outside the submitted work. SC reports institutional grant and honoraria from SIS Medical, institutional grant and honoraria from Boston Scientific, honoraria from Astra Zeneca, Translumina and Teleflex, outside the submitted work. The other authors declare no potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}